Form 4: Neurocrine Biosciences CHRO RSU Vesting & Tax Withholding

Neurocrine Biosciences' Chief Human Resources Officer, Julie Cooke, reported the vesting of 1,741 restricted stock units and the withholding of 997 shares for tax obligations.

Summary

• Julie Cooke, Chief Human Resources Officer of Neurocrine Biosciences, reported transactions related to her beneficial ownership of company common stock.
• On January 31, 2026, 1,741 Restricted Stock Units (RSUs) vested, representing a contingent right to receive one share of common stock per RSU.
• Concurrently, 997 shares of common stock were withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements associated with the RSU vesting.
• The shares withheld for tax purposes were valued at $136.06 per share.
• Following these transactions, Julie Cooke beneficially owns 27,602 shares of Neurocrine Biosciences common stock.
• The RSU award was originally granted on January 31, 2022, with vesting occurring in four annual tranches.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard executive compensation practices and the retention of a key officer. It does not indicate any significant operational or financial changes for the company.

Positives

• The vesting of Restricted Stock Units represents a routine component of executive compensation, aligning the executive's interests with long-term company performance.
• The executive received 1,741 shares of common stock from the RSU vesting, demonstrating continued equity ownership.

Negatives

• 997 shares were withheld by the company to cover tax obligations, reducing the net number of shares received by the executive from the vesting event.

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax withholding are standard practices for executive compensation across publicly traded companies, particularly prevalent in the biotechnology and pharmaceutical sectors. This filing reflects a routine compensation event for a key executive at Neurocrine Biosciences, aligning executive incentives with long-term company performance and shareholder value.

Comparison to Industry Standards

• RSU vesting with tax withholding is a common compensation structure across publicly traded companies, especially in high-growth sectors like biotech.
• Companies such as Amgen, Gilead Sciences, and Biogen frequently utilize similar equity compensation plans for their executives, where a portion of vested shares is automatically withheld to cover statutory tax liabilities.
• This practice is standard and aligns with typical corporate governance and compensation benchmarks within the industry.

Related Party Transactions

• The vesting of 1,741 Restricted Stock Units (RSUs) for Julie Cooke, Chief Human Resources Officer, and the subsequent withholding of 997 shares by Neurocrine Biosciences, Inc. to cover tax obligations, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine compensation event. It reflects the ongoing cost of executive compensation through equity dilution, which is generally factored into company valuation.
• Employees: No direct impact beyond the reporting person.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (RSU vesting and tax withholding) and does not provide new information that would alter the fundamental investment thesis for Neurocrine Biosciences. It is a standard disclosure and does not warrant a change in investment recommendation.

Keywords

NBIX, Neurocrine Biosciences, Form 4, Insider Transaction, RSU Vesting, Executive Compensation, Julie Cooke, Stock Ownership